Gabrielle Abelard
Psychiatric/Mental Health · Stoughton, MANPI 1811198740
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 86.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $4,458 and has fallen 98.6% since, to $63 in 2025. Among psychiatric/mental health clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 37 payments — averaging $137.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$4K
- AbbVie$240
- Johnson & Johnson$157
- Otsuka America Pharmaceutical, Inc.$73
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$72
- Vanda Pharmaceuticals Inc.$33
- plus $104 from 5 others
What the payments were for
- Consulting fees$3,00059%
- Travel & lodging$1,02220%
- Food & beverage$1,03320%
- Education$471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 9 | $4,422 |
| AbbVie | 14 | $240 |
| Johnson & Johnson | 4 | $157 |
| Otsuka America Pharmaceutical, Inc. | 2 | $73 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $72 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Supernus Pharmaceuticals, Inc. | 1 | $26 |
| Alkermes, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
How this compares
$5,101 in reported general payments places this provider in the 95th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
See all psychiatric/mental health providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 11 | $15,368 |
| Trifluoperazine Hcl | 13 | $1,947 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 17 | $837 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 31 | $801 |
| Aripiprazole | 16 | $669 |
| Bupropion XlBupropion Hcl | 42 | $548 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $528 |
| Clonazepam | 42 | $462 |
| Lamotrigine | 46 | $455 |
| Escitalopram Oxalate | 30 | $348 |
| Sertraline Hcl | 18 | $263 |
| Fluoxetine Hcl | 19 | $194 |
| Alprazolam | 17 | $189 |
| Citalopram HbrCitalopram Hydrobromide | 14 | $119 |
| Paroxetine Hcl | 11 | $109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $240 | $15,36811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
Other psychiatric/mental health in Stoughton
- Margaret BrownStoughton$13K
- Brianne LienkampMarion$121K
- Ashley BakerQuincy$54K
- Brian BanksPembroke$47K
- Anne-Margaret BotelhoMattapoisett$46K
- Matthew PeculisWalpole$41K
- Sherrie UrenaWorcester$21K
- Irina DauphineeHanover$18K
- Schree PettigrewNew Bedford$18K
- Sherryl RosenLynn$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.